|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
National Crisis Supercedes Coverage Debate
Efforts to craft a Medicare pharmacy benefit may be sidelined by repercussions from the September attack.
Advertisement
Articles in this issue
about 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
PBMs: Merck-Medco in the Hot Seatabout 24 years ago
A Five-Year Forecast: Clear Seas Ahead?about 24 years ago
Weak Bones, Strong Marketabout 24 years ago
Approvals: Novartis’ Silver Liningabout 24 years ago
Pfizer and others Pitch Inabout 24 years ago
Oncology: EMEA Approval Lagsabout 24 years ago
Illegal Sales in Indiaabout 24 years ago
Health Plan Premiums: Pharma Takes the Blameabout 24 years ago
Little Elan Becomes a Big DealNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5
